FIERCELY FOCUSED
ON SCIENCE

Ublituximab is a novel glycoengineered monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. When ublituximab binds to the B-cell it triggers a series of immunological reactions (including antibody-dependent cellular cytotoxicity [ADCC] and complement dependent cytotoxicity [CDC]), leading to destruction of the cell. Additionally, ublituximab is uniquely designed to lack certain sugar molecules normally expressed on the antibody. Removal of these sugar molecules, a process called glycoengineering, has been shown to enhance the potency of ublituximab, especially the ADCC activity.

Targeting CD20 using monoclonal antibodies has proven to be an important therapeutic approach for the management of B-cell malignancies and autoimmune disorders, both diseases driven by the abnormal growth or function of B-cells.

Please click here to view our Publications Page.

Azercabtagene zapreleucel (“azer-cel”) is an investigational anti-CD19 allogeneic chimeric antigen receptor (CAR) T cell therapy. In contrast to autologous CAR T cell therapies which are made individually from a patient’s own cells, azer-cel is an allogeneic or “off-the-shelf” therapy made from donor-derived T cells, modified using a proprietary gene editing technology.  Azer-cel recognizes the well characterized B cell surface protein CD19 and is designed to avoid graft-versus-host disease, a significant complication associated with other donor-derived, cell-based therapies.